Apixaban in Atrial Fibrillation

8th March 2013 by Louise Hudman

This guidance is another new drug for the use in AF as an anticoagulant. It is a Factor Xa inhibitor and is more effective than warfarin. It hasn’t been shown to be more effective than Rivaroxaban and Dabigatran. It has the lowest bleeding risk. As always, we should wait for local prescribing advice before using.

It can be considered if the patient has non-valvular AF and at least 1 of:

  • Prior stroke or TIA
  • 75 or older
  • Hypertension
  • Diabetes
  • Symptomatic heart failure

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"LocumDeck really is brilliant. I've always relied on my own system - I never put my faith in any other system before LocumDeck.

But I was genuinely buzzing when I used it yesterday - how easy it was to use and how many other things it does. It will significantly change and improve my invoicing and end of the month. "

Dr Kathryn Furneaux

See the full list of features within our NASGP membership plans

Membership